Last year the FDA’s Center for Drug Evaluation and Research issued dozens warning letters for manufacturing issues to pharma companies outside the U.S. One country in particular received the highest amount.
We originally posted on this last October (on our LinkedIn page, here) and now that the final numbers are in for 2019 we thought it would be good to revisit the topic.
With over 90 FDA warning letters issued throughout 2019, its critical to get quality control correct throughout the entire #pharma process, starting with #manufacturing and continuing along with the research, development and testing processes.
If the foundation isn’t solid to begin with, everything you build on top is useless. Do you agree?
Being successfully GMP, GLP, GCP certified and FDA audited multiple times, and with over 20-years experience of supporting the entire pharma cycle from start to finish, why not let QUINTA-ANALYTICA be your partner to success?
Challenges of a large-scale study of breast cancer
Our bioanalytical experts and a high-profile client team up for the development of a new therapy for breast cancer.
29 June 2023
EU funding for Quinta-Analytica laboratory in Brno (CZ) was succesfully completed.
After two years, the project to finance new equipment for the Quinta-Analytica laboratory in Brno was successfully completed. The investment from European Regional Development Fund was used in this project.
22 June 2023
Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies
EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency